Double Positivity for HPV-DNA/p16 is the Biomarker with Strongest Diagnostic Accuracy and Prognostic Value for Human Papillomavirus Related Oropharyngeal Cancer Patients
Overview
Authors
Affiliations
Background: The etiologic role of human papillomaviruses (HPV) in oropharyngeal cancer (OPC) is well established. Nevertheless, information on survival differences by anatomic sub-site or treatment remains scarce, and it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value.
Methods: We conducted a retrospective cohort study of all patients diagnosed with a primary OPC in four Catalonian hospitals from 1990 to 2013. Formalin-fixed, paraffin-embedded cancer tissues were subjected to histopathological evaluation, DNA quality control, HPV-DNA detection, and p16/pRb/p53/Cyclin-D1 immunohistochemistry. HPV-DNA positive and a random sample of HPV-DNA negative cases were subjected to HPV-E6*I mRNA detection. Demographic, tobacco/alcohol use, clinical and follow-up data were collected. Multivariate models were used to evaluate factors associated with HPV positivity as defined by four different HPV-relatedness definitions. Proportional-hazards models were used to compare the risk of death and recurrence among HPV-related and non-related OPC.
Results: 788 patients yielded a valid HPV-DNA result. The percentage of positive cases was 10.9%, 10.2%, 8.5% and 7.4% for p16, HPV-DNA, HPV-DNA/HPV-E6*I mRNA, and HPV-DNA/p16, respectively. Being non-smoker or non-drinker was consistently associated across HPV-relatedness definitions with HPV positivity. A suggestion of survival differences between anatomic sub-sites and treatments was observed. Double positivity for HPV-DNA/p16 showed strongest diagnostic accuracy and prognostic value.
Conclusions: Double positivity for HPV-DNA/p16, a test that can be easily implemented in the clinical practice, has optimal diagnostic accuracy and prognostic value. Our results have strong clinical implications for patients' classification and handling and also suggest that not all the HPV-related OPC behave similarly.
HPV Biomarkers in Oral and Blood-Derived Body Fluids in Head and Neck Cancer Patients.
Galati L, Tagliabue M, Gheit T, De Berardinis R, Maffini F, McKay-Chopin S J Med Virol. 2025; 97(3):e70278.
PMID: 40052199 PMC: 11886502. DOI: 10.1002/jmv.70278.
Sherief P A, Madhavan Nair L, Ravikumar R, George P, Cessal Thommachan K, Rafi M Cureus. 2025; 17(1):e77162.
PMID: 39925561 PMC: 11806965. DOI: 10.7759/cureus.77162.
Boscolo-Rizzo P, Polesel J, Menegaldo A, Sia E, Stellin M, Tirelli G Head Neck Pathol. 2024; 18(1):101.
PMID: 39404976 PMC: 11480278. DOI: 10.1007/s12105-024-01713-7.
Brooks J, Zheng Y, Hunter K, Willcox B, Dunn J, Nankivell P Front Oncol. 2024; 14:1428741.
PMID: 39328208 PMC: 11424609. DOI: 10.3389/fonc.2024.1428741.
Priyatha V, Gupta H, Narsapuram P, Ahmed F, Alhussain H, Arfa A Cureus. 2024; 16(7):e63594.
PMID: 39087192 PMC: 11290380. DOI: 10.7759/cureus.63594.